News coverage about Medtronic (NYSE:MDT) has trended somewhat positive on Monday, according to Accern. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Medtronic earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave media coverage about the medical technology company an impact score of 46.5952692348416 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Medtronic continues to push outcome-based contracts: 5 things to know (beckersspine.com)
- Global Laparoscopic Devices Market 2018 – EthiconEndo-Surgery, Olympus, Medtronic(Covidien), Stryker … (nwctrail.com)
- Global Heart Pacemaker Market 2018- Boston Scientific Corporation, Medtronic, St. Jude Medical, Biotronik, Cook … (anglophonetribune.com)
- Medtronic (MDT) Lifted to “Buy” at Bank of America (americanbankingnews.com)
- Heart Lung Machine Market Growth Prospect with key players: Medtronic, Sorin, MAQUET, Terumo (journalhealthcare.com)
NYSE:MDT traded down $2.74 during trading hours on Monday, reaching $77.48. The company’s stock had a trading volume of 6,409,695 shares, compared to its average volume of 5,672,405. The company has a market capitalization of $108,728.03, a price-to-earnings ratio of 16.84, a price-to-earnings-growth ratio of 2.25 and a beta of 0.94. Medtronic has a 12 month low of $76.41 and a 12 month high of $89.72. The company has a quick ratio of 2.09, a current ratio of 2.43 and a debt-to-equity ratio of 0.51.
Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, February 20th. The medical technology company reported $1.17 EPS for the quarter, topping analysts’ consensus estimates of $1.16 by $0.01. The company had revenue of $7.37 billion during the quarter, compared to the consensus estimate of $7.20 billion. Medtronic had a net margin of 9.44% and a return on equity of 12.65%. Medtronic’s revenue for the quarter was up 1.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.12 earnings per share. sell-side analysts expect that Medtronic will post 4.74 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 13th. Investors of record on Friday, March 23rd will be paid a $0.46 dividend. This represents a $1.84 dividend on an annualized basis and a yield of 2.37%. The ex-dividend date of this dividend is Thursday, March 22nd. Medtronic’s dividend payout ratio (DPR) is 40.00%.
Several research firms have recently weighed in on MDT. Oppenheimer reaffirmed a “buy” rating on shares of Medtronic in a research note on Tuesday, March 20th. Morgan Stanley decreased their price target on shares of Medtronic from $95.00 to $90.00 and set an “equal weight” rating for the company in a research note on Thursday. Citigroup reaffirmed a “buy” rating and set a $93.00 price target (down previously from $100.00) on shares of Medtronic in a research note on Thursday, February 22nd. BMO Capital Markets lifted their price target on shares of Medtronic to $94.00 and gave the company an “outperform” rating in a research note on Tuesday, December 12th. Finally, TheStreet downgraded shares of Medtronic from a “b” rating to a “c+” rating in a research note on Tuesday, February 20th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and sixteen have given a buy rating to the stock. Medtronic currently has a consensus rating of “Buy” and an average price target of $91.24.
In other news, VP Richard Kuntz sold 78,526 shares of the company’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $86.21, for a total transaction of $6,769,726.46. Following the transaction, the vice president now directly owns 149,761 shares of the company’s stock, valued at $12,910,895.81. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director James T. Lenehan sold 1,306 shares of the company’s stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $83.56, for a total value of $109,129.36. The disclosure for this sale can be found here. Insiders sold 130,469 shares of company stock valued at $11,016,054 in the last three months. 0.31% of the stock is currently owned by insiders.
Medtronic Company Profile
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.